Allergan Reports First Quarter 2012 Operating Results

Allergan, Inc. (NYSE:AGN) today announced operating results for the quarter ended March 31, 2012. Allergan also announced that its Board of Directors has declared a first quarter dividend of $0.05 per share, payable on June 14, 2012 to stockholders of record on May 24, 2012.

Operating Results Attributable to Stockholders

For the quarter ended March 31, 2012:
  • Allergan reported $0.74 diluted earnings per share attributable to stockholders compared to $0.51 diluted earnings per share attributable to stockholders for the first quarter of 2011.
  • Allergan reported $0.86 non-GAAP diluted earnings per share attributable to stockholders compared to $0.77 non-GAAP diluted earnings per share attributable to stockholders for the first quarter of 2011, an 11.7 percent increase.

Product Sales

For the quarter ended March 31, 2012:
  • Allergan reported $1,365.7 million total product net sales. Total product net sales increased 9.0 percent compared to total product net sales in the first quarter of 2011. On a constant currency basis, total product net sales increased 10.4 percent compared to total product net sales in the first quarter of 2011.
    • Total specialty pharmaceuticals net sales increased 10.8 percent, or 12.2 percent on a constant currency basis, compared to total specialty pharmaceuticals net sales in the first quarter of 2011.
    • Total medical devices net sales increased 0.8 percent, or 2.0 percent on a constant currency basis, compared to total medical devices net sales in the first quarter of 2011.

“In the first quarter Allergan delivered strong operating results as we continued to benefit from product approvals and operating in many growing markets,” said David E.I. Pyott, Allergan’s Chairman of the Board, President and Chief Executive Officer. “In addition, as discussed at our Research & Development Technology Review in March, we have a robust R&D pipeline that should fuel additional growth over the long-term.”

If you liked this article you might like

Elizabeth Warren Slams Wells Fargo, Equifax: Cramer's Top Takeaways

Centene: Cramer's Top Takeaways

The Pitney Bowes Transformation: Cramer's Top Takeaways

Healthcare Trust of America, Marathon Petroleum: 'Mad Money' Lightning Round

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)